Analysis of the Diagnosis and Treatment of Recurrent Rupture and Hemorrhage of Ovarian Corpus Luteum Cyst Induced by Imatinib

Abstract

Objective: Rupture and hemorrhage of corpus luteum cyst is one of the common acute abdominal diseases in gynecology, which occurs in the middle and late menstrual cycle, and is often seen in women of childbearing age, often under the inducement of exercise and sexual life. There are few reports about drug-induced rupture and hemorrhage of corpus luteum cyst. Chronic myeloid leukemia (CML) is a common hematological disease and a chronic clonal myeloproliferative disease. Imatinib is a first-line drug for the treatment of chronic myeloid leukemia, and its efficacy and safety have been widely recognized, but there are still some adverse reactions. Among them, it is rare that the drug causes ovarian corpus luteum rupture and bleeding. In our clinical work, we just treated a patient with recurrent ovarian luteal cyst rupture and bleeding from imatinib, and followed up the whole course of the patient's pathogenesis, diagnosis and treatment effect. Therefore, this paper analyzes the clinical data and treatment of the case, in order to improve the clinical understanding and treatment of recurrent ovarian luteal cyst rupture and hemorrhage induced by imatinib. Methods: The clinical data and treatment of 1 case of recurrent ovarian corpus luteum cyst rupture bleeding from imatinib were analyzed, and the therapeutic effect was followed up. Results: Imatinib led to 6 times of corpus luteum rupture bleeding, which were successfully treated with conservative treatment. After taking Diane-35, the patient did not have corpus luteum rupture bleeding once again. And no adverse drug reactions. Conclusion: Imatinib can cause recurrent ovarian luteal cyst rupture and bleeding, conservative treatment is often effective. Diane-35 can effectively prevent and treat recurrent ovarian luteal cyst rupture and bleeding induced by imatinib. And the incidence of adverse drug reactions was low. But the specific mechanism that imatinib causes rupture of recurrent ovarian luteal cyst is unclear.